CURRICULUM VITAE MOHSEN I. AFOUNA-AUG-2016
ADDRESS OFFICE Al-Azhar University College of Pharmacy Department of Pharmaceutics Nasr City-11567 Cairo, Egypt Phone No.: +002-02-(226)-33050 Ext. 185 (W) Cell Phone: +002-01-(099)-105205/+002-01-(222)-559070 +002-02-(358)-74632 (H) Email address: mafouna@paharm.asu.edu.eg mafonah@kau.edu.sa
PROFILE: Highly motivated scientist (teacher, researcher) with expertise in development of topical, ocular and transdermal drug delivery systems. Experienced in development of non-clinical methodologies to assess the topical efficacy of various antiviral agents. Outstanding teaching & research experience in pharmaceutical sciences, development and management of scientific research projects combined with fluency in English and Arabic. Author of several recent articles, review articles and chapter in textbooks. High experience regarding oral, ocular, topical, transdermal, chirality, physical & clinical pharmacy, Biopharmaceutics & pharmacokinetics. Excellent written and oral communication skills with supervisory and teaching experience. Driven pharmaceutical scientist, love to work in a dynamic teaching, research and development environment. EDUCATION 1998
Ph.D. (Pharmaceutical Sciences), Pharmaceutics in a joint supervision program between Department of Pharmaceutics & Pharmaceutical Technology, College of Pharmacy, AlAzhar University (Egypt) and Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. 1995 M. Sc. Pharmaceutical Sciences (Pharmaceutics), College of Pharmacy, Al-Azhar University. Nasr City, Cairo, Egypt. 1987 B. Sc., Pharmacy, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. EXPERIENCES Professor & Chairman of Department of Pharmaceutics & Pharmaceutical Technology, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt, 2012 – Present. 2. Associate Professor of Pharmaceutics and Clinical Pharmaceutics, Department Pharmaceutics and Clinical Pharmaceutics, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. 2010-2014. 3. Associate Professor of Pharmaceutics and Clinical Pharmaceutics, Departments of Pharmaceutics, and Clinical Pharmacy, College of Pharmacy, King Abdul Aziz University, Jeddah, KSA, 2006-to-2010 1.
1
4. 5. 6. 7. 8. 9. 10. 11.
Clinical Pharmacy, College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 2005-2006. Research Scientist, (Assistant Research Professor), Department of Pharmaceutical Sciences, University of Arkansas of Medical Sciences (UAMS), College of Pharmacy, Little Rock, AR 72205, USA, (~4-years) 2002-2005. Assistant Professor of Pharmaceutics and Clinical Pharmaceutics, Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. 1998-March 2002. Ph.D. studies with Distinguished Professor Dr. William I. Higuchi, Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lack City, UT, USA. 1996-1998. Assistant Lecturer, Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. 1995-1996. Teaching Assistant, Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt. 1989-1995. Pharmacist in the Egyptian Army Forces “mandatory military service”, 1988-1989. Community Pharmacist in the private sector pharmacies, 1987-to-1988. PUBLICATIONS 1. Mohsen I. Afouna, Hany M. Ibrahim, Hatem R. Ismail. Non-viral Victors in Gene Therapy: Current Status and Future Perspectives (Part-I), in Multi-Volume SET (I-XXVII) "Pharmaceutical Nanotechnology", Ed., Alex Grumezescu, Elsevier Pub. Inc., January, (2017) (In press). 2. Mohsen I. Afouna, Hany M. Ibrahim, Hatem R. Ismail. Non-viral Victors in Gene Therapy: Current Status and Future Perspectives (Part-II), in Multi-Volume SET (I-XXVII) "Pharmaceutical Nanotechnology", Ed., Alex Grumezescu, Elsevier Pub. Inc., January, (2017) (In press). 3. Mohamed F. Ibrahim, Alaa Zaky, Mohsen I. Afouna, Ahmed M. Samy. Preparation and in-vitro evaluation of resealed erythrocytes as new trend in treatment of Asthma. International Journal of Drug Delivery Technology (IJDDT), (2016), (In press). 4. Mohsen I. Afouna, Ismail HR, Ibrahim HM, Naim AB, El-Marzoqi A. Maximization of the in vitro transcorneal release and the in vivo IOP-lowering effects of Latanoprost ophthalmic gel formulations using Azone as a penetration enhancer and Carbopol-974® as a mucoadhesive. J. Excipients and Food Chem. 7 (2), 20-35; (2016). 5. Mohamed A. Akl, Alma Kartal-Hodzic, Timo Oksanen, Hatem R. Ismael, Mohsen I. Afouna, Marjo Yliperttula, Ahmed M. Samy and Tapani Viitala. Factorial design formulation optimization and In vitro characterization of curcumin loaded PLGA nanoparticles for colon delivery. Journal of drug delivery science and technology, 32 (A), 10-20; (2016). 6. Rashad M. Kaoud, Mohsen I. Afouna, Ahmed M. Samy and Alaa A. Kassem. Glimepiride-solid lipid nanoparticles as a tool to control blood glucose level in diabetic patients, Part 2: Effect of storage, stability study and anti-diabetic effect. J. of Life Medicine, 4(1), 1-15; (2016). 7. Mohamed A. Akl, Alma Kartal-Hodzic, Timo Oksanen, Hatem R. Ismael, Mohsen I. Afouna, Marjo Yliperttula, Tapani Viitala, Ahmed M. Samy. Enhanced mucoadhesion and cellular uptake of curcumin delivered in chitosan modified PLGA Nanosphere. J. of Life Medicine, 4(1), 39-54; (2016). 8. Rashad M. Kaoud, Mohsen I. Afouna, Ahmed M. Samy and Alaa A. Kassem. Glimepiride-solid lipid nanoparticles as a tool to control blood glucose level in diabetic patients, Part 1: Design, formulation, characterization and rheological properties. J. of Life Medicine, 4(1), 16-38; (2016). 9. Glimepiride-solid lipid nanoparticles as a tool to control blood glucose level in diabetic patients, Part 2: Effect of storage, stability study and anti-diabetic effect, Rashad M. Kaoud, Mohsen I. Afouna, Ahmed M. Samy and Alaa A. Kassem. J. of Life Medicine, 4(1), 1-15; (2016). 10. Mohamed A. Akl, Alma Kartal-Hodzic, Timo Oksanen, Hatem R. Ismael, Mohsen I. Afouna, Marjo Yliperttula, Tapani Viitala, Ahmed M. Samy. Enhanced mucoadhesion and cellular uptake of curcumin delivered in chitosan modified PLGA Nanosphere. J. of Life Medicine, 4(1), 39-54; (2016). 11. Mohamed F. Ibrahim, Alaa Zaky, Mohsen I. Afouna, Ahmed M. Samy. Preparation and in-vitro evaluation of resealed erythrocytes as new trend in treatment of Asthma. International Journal of Drug Delivery Technology (IJDDT), in press.Mohamed, (2016).
2
12. A. Akl, Alma Kartal-Hodzic, Timo Oksanen, Hatem R. Ismael, Mohsen I. Afouna, Marjo Yliperttula, Tapani Viitala, Ahmed M. Samy. Enhanced Mucoadhesion and Cellular Uptake of Curcumin Delivered in Chitosan Modified PLGA Nanosphere. Journal of Life Medicine, 4,(1): 39-54; 9; (2016). 13. Mohamed A. Akl, Alma Kartal-Hodzic, Timo Oksanen, Hatem R. Ismael, Mohsen I. Afouna, Marjo Yliperttula, Ahmed M. Samy, Tapani Viitala. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. Journal of Drug Delivery Science and Technology, 32,: 10-20; (2016). 14. Osama Abdelhakim Aly Ahmed, Mallesh Kurakula, Zainy Mohamed Banjar, Mohsen I. Afouna. Quality by Design Coupled with Near Infrared in Formulation of Transdermal Glimepiride Liposomal Films. Journal of Pharmaceutical Sciences; (2015) Apr 13. doi: 10.1002/jps.24448. 15. Ahmed Samir Zidan, Osama A. Ahmed, Mohsen I. Afouna, Khalid M. Elsay, Ashraf A. Naim, Alaa M. Khedr and Zainy M. Banjar. Optimization of Self-Nanoemulsifying Systems for the Enhancement of In Vivo Hypoglycemic Efficacy of Glimepiride Transdermal Patches. Journal of “Expert Opinion in Drug Delivery”. 11(7):1005-13; (2014) 16. Osama A. Ahmed, Ashraf B. Abde-Naim, Alaa Khedr, Zainy Banjar, Mohsen I. Afouna*. Enhancement of In Vitro Skin Transport and In Vivo Hypoglycemic Efficacy of Glimepiride Transdermal Patches. Tropical Journal of Pharmaceutical Research. 2014; 13 (8): 1207-13. 17. Mohsen I. Afouna* and Ashraf A. Naim. Optimization of the In Vitro Transcorneal Release and the In Vivo IOP-Lowering Effects of Latanoprost Ophthalmic Gel Formulations Using Azone™ as a Penetration Enhancer and Carbopol-974® as a Mucoadhesive. Am. J. PharmTech Res. 1-23,4(1): 642-63 (2014). 18. Mohsen I. Afouna*. Amal K. Hussein and Osama A. Ahmed. Influence of the Interplay between Azone™ as Permeation Enhancer and Carbopol-974® as a Mucoadhesive upon the In Vitro Transcorneal Release and the In Vivo Antiglaucoma Effect of S-Timolol Maleate Ophthalmic Gel Formulations. International Journal of Pharma Tech Research, (2014). 19. Mohsen I. Afouna* Enantioselectivity Transport of Timolol Maleate through Hairless Mice Skin is a SingleValued Function of the Concentrations of Chiral Terpene Enhancer (D-Limonene). Am. J. PharmTech Res. 3(6),387-402, (2013) 20. Mohsen I. Afouna* Concentration-dependent enantioselective transport of chiral timolol maleate across hairless mice skin upon using various concentrations of chiral terpene enhancer (D-Limonene). Journal of Excipients and Food Chemicals. 4 (4), 158-168, (2013). 21. Amal K. Hussein, Shahira F. El-Menshawe, Mohsen I. Afouna. Improved In-vitro Dissolution and In-vivo Oral Bioavailability of Silymarin, from Liquid-Filled Hard Gelatin Capsules of Semisolid Dispersion Using Gelucire 44/14 as a Carrier, Pharmazie 67: 1–6, doi: 10.1691/ph.2012.1109, (2012). 22. Mohsen I. Afouna. Influence of Different Chiral Terpinen-4-ol Enhancer Concentrations upon Solubility and Percutaneous Transport of Timolol Maleate Individual Isomers and Racemate Using Hairless Mice Skin: A Comparative Study. Egyp. J. Sci. and Biotech. 3, 145-161, (2011). 23. Amal K. Hussein, Mohamed A. Ibrahim, Mohamed A. Amin, Osama A. A. Ahmed, Mohsen I. Afouna. Improved In Vitro Dissolution Parameters and In Vivo Hypolipidimic Efficiency of Atorvastatin Calcium through the Formation of Hydrophilic Inclusion Complex with Cyclodextrins. Journal of Drug Development Research. 72, 1-12, (2011). 24. Mohsen I. Afouna, Ashraf A. Naim, Ala'a Khedr and Adnan El-Marzoqi. Influence of Various Concentrations of Terpene-4-ol enhancer and Carbopol-934 Mucoadhesive upon the In Vitro Ocular Transport and the In Vivo Intraocular Pressure Lowering Effects of Dorzolamide Ophthalmic Formulations Using Albino Rabbits, Journal of Pharmaceutical Sciences; 99(1):119-27, (2010). 25. Mohsen I. Afouna, Ala'a Khedr and Adnan El-Marzoqi. Effects of (-)-Carveol and HPMC upon the In Vitro Ocular Transport and the In Vivo Intraocular Pressure Lowering Effects of Dorzolamide Formulations in Normotensive New Zealand Rabbits. Journal of Drug Development Research, 70(3): 191-198 (2009). 26. A. Zaghloul, E. Taha, Mohsen I. Afouna, I. Khattab1, S. Nazzal. Ex vivo Mucoadhesion and In Vivo Bioavailability Assessment and Correlation of Ketoprofen Tablet Dosage Forms Containing Bioadhesives. Pharmazie 62: 346–350 (2007).
3
27. Ibrahim S Khattab, Abdel-Azim A Zaghloul, Mohsen I. Afouna. Studies on the Development of Rapidly Disintegrating Hyoscine Butylbromide Tablets. Drug Discov Ther 1(1):61-64 (2007). 28. Mohsen I. Afouna. Enantioselective Transport of Chiral -Blocker Timolol Maleate through Hairless Mice Skin upon Using Various Concentrations of Chiral Terpene Enhancer (-)– Carveol. Egyptian Journal of Biomedical Sciences, 18, 163-179, (2005). 29. Mohsen I. Afouna, Ibrahim S. Khattab and Indra K. Reddy. Preparation and Characterization of Demeclocycline Liposomal Formulations and Assessment of their Intra-ocular Pressure Lowering Effects using rabbit model. Journal of Toxicology-Cutaneous and Ocular Toxicology, 24 (2), 111-124, (2005). 30. Touitou Elka, Biana Godin, Kommuru R. Thirumala, Mohsen I. Afouna, Reddy K. Indra, Skin Transport of Optically Active Stereoisomers, In: Chirality in Drug Design and Development, Reddy K. Reddy, Reza Mehvar (Editors), Marcel Dekker, Inc., New York, March, (2004). 31. Hutak CM, Kavanagh ME, Mohsen I. Afouna, Khan M. A. and Reddy I. K. Using of SIRC Rabbit Corneal Cell Lines Grown on Polycarbonate- or Polyester-Based Filters for the in Vitro Corneal Transport//Toxicity Screening Using Pilocarpine with and without Benzalkonium Chloride. Journal of Toxicology-Cutaneous and Ocular Toxicology, 22 (1,2), 101-114, (2003). 32. Mohsen I. Afouna, Fincher T. K., Khan M. A. and Reddy I. K. Percutaneous Permeation of Optically Active and Racemic Mixtures of Chiral Drugs and Prediction of their Flux Ratios Using Thermal Data: A Pharmaceutical Perspective. Chirality. 15(5):456-65. Review (2003). 33. Mohsen I. Afouna, Fincher T. K., Abdel Azim A. Zaghloul, and Reddy I. K. Effect of Azone upon the In vivo Antiviral Efficacy of Cidofovir or Acyclovir Topical Formulations against Cutaneous HSV-1 Infections and Its Correlation with Skin Target Site Free Drug Concentration Using Hairless Mice. International Journal of Pharmaceutics, 253 (1-2), 159 – 168, (2003). 34. Mohsen I. Afouna, Influence of Various Azone Concentrations upon Skin Target Site Free Drug Concentration (C*) of Bromovinyldeoxyuridine (BVDU) and Acyclovir (ACV) Formulations Using Hairless Mice: A Comparative Study. Az. J. Pharmaceutical Sciences., 28: 26-37, (2001). 35. Mohsen I. Afouna, Mehta, S. C., Ghanem, A-H., Higuchi, W. I., Kern, E. R., DeClercq, E., and El-Shattawy, H. Influence of the Treatment Protocol upon the In-Vivo Efficacy of Cidofovir (HPMPC) and Acyclovir (ACV) Formulations in Topical Treatment of Cutaneous HSV-1 Infections in Hairless Mice, Journal of Pharmaceutical Sciences, 88(5): 530-534 (1999). 36. Mohsen I. Afouna, Mehta, S. C., Ghanem, A-H., Higuchi, W. I., Kern, E. R., and DeClercq, E., and ElShattawy, H. Influence of when Therapy is Initiated upon the In Vivo Efficacy of HPMPC in Treatment of Cutaneous HSV-1 Infections in Hairless Mice. Journal of Controlled Release, Proceeding, (5): 593-596 (1998). 37. Mohsen I. Afouna, Mehta, S. C., Ghanem, A-H., Higuchi, W. I., Kern, E. R., DeClercq, E., and El-Shattawy, H. Assessment of Correlation between Skin Target Site Free Drug Concentration and the In-Vivo Topical Efficacy in Hairless Mice for (E)-5-(2-Bromovinyl)-2-Deoxyuridine and Acyclovir Formulations. Journal of Pharmaceutical Sciences, 87(8): 917-921 (1998). 38. Mehta, S. C., Mohsen I. Afouna, Ghanem, A-H., Higuchi, W. I. and Kern, E. R. Relationship of Skin Target Site Free Drug Concentration (C*) to the In-Vivo Efficacy: An Extensive Evaluation of the Predictive Value of the C* Concept Using Acyclovir as a Model Drug. Journal of Pharmaceutical Sciences, 86(7): 797-801 (1997). 39. Samir C. Mehta, Mohsen I. Afouna, Abdel-Halim Ghanem, William I. Higuchi, Earl R. Kern and Hamed El-Shattawy. The relationship of basal cell layer drug concentration (C*) to the antiviral efficacy: A rigorous evaluation of the C* concept for predicting the entire range of topical efficacy of acyclovir formulations in the treatment of cutaneous HSV-1 infections in hairless mice, Antiviral Research, 34, P-80 (1997) 40. Mohsen I. Afouna, Ph.D. Dissertation, Optimization of the Availability of Antiviral Agent Using Topical Application in a joint supervision program between the University of Al-Azhar (Egypt) and the University of Utah, SLC, UT (USA), (1998). 41. Mohsen I. Afouna, Master’s Thesis, Pharmaceutical Studies on the Availability of Enalapril Maleate, AlAzhar University, (1995).
4
PUBLISHED CHAPTERS 42. Touitou Elka, Biana Godin, Kommuru R. Thirumala, Mohsen I. Afouna, Reddy K. Indra. Skin Transport of Optically Active Stereoisomers, In: “Chirality in Drug Design and Development”. Reddy K. Reddy, Reza Mehvar (Editors), Marcel Dekker, Inc., New York, March, (2004). SELF-PUBLISHED BOOKS FOR PHARMACY STUDENTS: 1. Mohsen I. Afouna. “Introduction to the Pharmaceutical Dosage Forms” 2. Mohsen I. Afouna. “Sterile Dosage Forms: Preparation and Clinical Applications” 3. Mohsen I. Afouna. “Basics of Physical Pharmacy" 4. Mohsen I. Afouna. “Biopharmaceutical and Clinical Pharmacokinetics" ABSTRACTS PRESENTED IN INTER/NATIONAL MEETINGS & WORKSHOPS 1. Mohsen I. Afouna. Invited speaker, Generic Pharma Conference (Innovations in Exertion of Pharmacy), Valencia, Spain, Oct31- Nov 02 (2016). 2. Mohsen I. Afouna. Keynote/Invited speaker. 7th International Conference and Exhibition on Pharmacovigilance (Ensuring Safer Therapeutics in healthcare System), held in Vienna, Austria at August 22-24, (2016). 3. Mohsen I. Afouna. Keynote speaker/Review & Organizing committee member, International Pharmacy Conference (pharmacy 2016), Philadelphia, USA at July 14-15, (2016). 4. Mohsen I. Afouna. Keynote speaker/Review & Organizing committee member. Global Pharmaceutical Industry Summit (pharmacy 2016), held in Vienna, Austria at September 19-21, (2016). 5. Mohsen I. Afouna. Invited speaker. Asia Pasific Drug Formulation and Bioavailability Congress" (Drug Formulation 2016), Beijing, China, September 5-7, (2016). 6. Mohsen I. Afouna. Invited speaker. 6th annual Symposium of drug delivery Systems "Sym P207: Overcoming Barriers in Opthalmic Drug Delivery". Nanjing, China, November 16-19, (2016). 7. Mohsen I. Afouna. Keynote speaker/Review & Organization Committee Member. 9th World Drug Delivery Summit, Crown Plaza New Orleans, New Orleans, USA, June 30 - July 2, (2016). 8. Mohsen I. Afouna. Invited speaker. International Conference and Expo on Industrial Pharmacy, Dubai, UAE, April 28-29, (2016). 9. Mohsen I. Afouna, Keynote speaker/Review & Organizing Committee Member. 8th international conference and exhibition on pharmaceutics and novel drug delivery "Challenges and Advances in Drug Delivery Approches, Madrid, Spain, March 7-9, (2016). 10. Mohsen I. Afouna. Keynote speaker/Review & Committee Member. OMICS International Global Pharmaceutical Summit, Transdermal Drug Delivery: Recent Advances to narrow down the Gap between Reality and Expectations "Scrupulous knowledge of Pharmaceutical Sciences", Philadelphia, USA, 10-12 Aug., (2015). 11. Mohsen I. Afouna. Keynote speaker/Review & Committee Member. 4th International conference on pharmaceutical sciences. Dubai, UAE, January 21-22, (2015). 12. Mohsen I. Afouna. Assessment of [Bio]availability of Topical Formulations between Ambiguous Definition and Lack of Generalizable Approache (s), The Pharma Middle East. Dubai, UAE, November 02-04, (2015). 13. Mohsen I. Afouna, Transdermal Drug Delivery: Recent Advances to narrow down the Gap between Reality and Expectations. “Scrupulous knowledge of Pharmaceutical Sciences”, OMICS International Global Pharmaceutical Summit, Philadelphia, USA, 10-12 Aug., (2015). http://american.pharmaceuticalconferences.com/organizing-committee.php 14. Osama A. A. Ahmed, Tarek A. Ahmed, Mohsen I. Afouna, Ashraf B. Abdel-Naim, Alaa Khedr, Zainy M. Banjar. “Improved Skin Transport and Hypoglycemic Efficacy of Glimepiride Transdermal Patches”. 5thInternational Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, Crown Plaza, Dubai, UAE, March 16-18, (2015). 15. Osama A. A. Ahmed, Mohsen I. Afouna, Khalid M. El-Say, Ashraf B. Abdel-Naim, Alaa Khedr and Zainy M. Banjar. “Enhanced hypoglycemic efficacy of glimepiride transdermal patches utilizing self-nanoemulsifying systems: Optimization study”. The AAPS Annual Meeting, San Diego, CA, USA, Nov. (2014). 16. Mohsen Afouna. Keynote speaker. Vectors in Gene therapy: Recent Advances, Review Article. 3rd ScienceOne Conference on Drug Discovery and Development. Deira, Dubai, UAE, Supp, January 21-23, (2014). http://thescienceone.com/scddd
5
17. Mohamed A. Amin, Alaa zaky, Asmaa Elbakry, Gamal Zayed, Amal Hussein, Mohsen I. Afouna. Preparation and Characterization of Nanosuspensions to Improve the In Vitro Dissolution Rate and In Vivo Efficacy of Poorly Soluble Drug Using Nimesulide as a Model Drug. The AAPS Annual Meeting, Chicago, USA, Oct. (2012). 18. Amal K. Hussein, Shahira F. El-Menshawe, Mohsen I. Afouna. Improved In-Vitro Dissolution and In-Vivo Oral Bioavailability of Silymarin, from Liquid-Filled Hard Gelatin Capsules of Semisolid Dispersion Using Gelucire 44/14 as a Carrier. The AAPS Annual Meeting, Washington DC, USA, Oct. 2011. 19. Mohsen I. Afouna, Ala'a Khedr and Adnan El-Marzoqi. Influence of HPMC and (-)-Carveol upon the In Vitro Ocular Transport and the In Vivo Intraocular Pressure Lowering Effects of Dorzolamide Formulations Using New Zealand Rabbits. FIP Annual Meeting, Istanbul, Turkey, Sep. 2-9, (2009). 20.Mohsen I. Afouna, Ibrahim S. Khattab, Abdel-Azim A. Zaghloul, and Indra K. Reddy. Stereoselective Transport of Timolol Maleate across Hairless Mice Skin upon Using Different Concentrations of Chiral Terpinen-4-ol Enhancer. FIP Annual Meeting, Istanbul, Turkey, Sep. 2-9, 2009. 21. One-weak workshop for “ Quality Assurance and Academic Accreditation (QAAA) by a key figures and professional experts from USA, UK and Australia. KAU, Jeddah Saudi Arabia, (5-2007). 22.Mohsen I. Afouna, Ibrahim S. Khattab and Indra K. Reddy. Demeclocycline Liposomal Formulations: Preparation, Characterization and Assessment of their Intra-ocular Pressure Lowering Effects using rabbit model. The 9th International Pharmaceutical Sciences Meeting and Exposition, Dec. (2005). 23.Mohsen I. Afouna, [Bio]availability of Topical Formulations: From Ambiguous Definition to Lack of Generaliz[able] Approaches for Assessments. The 9th International Pharmaceutical Sciences Meeting and Exposition, Dec., Riyadh, KSA. (2005). 24.Training workshop in “Application of Software in the Design of Advanced Learning website (Web CT). Center of Development of Higher Education, King Abdul Aziz University, Jeddah, KSA. (2005). 25.Training workshop in “Effective Teaching Skills”. Center of Development of Higher Education, King Abdul Aziz University, Jeddah, KSA, (2005). 26.Training workshop in “Planning and Preparation of Multiple Choice Questions (MCQ) Exams. Center of Development of Higher Education, King Abdul Aziz University, Jeddah, KSA, (2005). 27.Mohsen I. Afouna, Ibrahim, E. A., Kassem, Fincher K. I. and Reddy K. I. Stability Characterization of Long-Acting Angiotensin Converting Enzyme Inhibitor; Enalapril Maleate Physical Mixtures with Selected Excipients Using Differential Scanning Calorimetry. The SRDG, Annual Meeting, Little Rock, AR, USA, May, (2002). 28.Mohsen I. Afouna, Ibrahim, E. A., Kassem, A., Fincher K. I. and Reddy K. I. Influence of Tablet Manufacturing Technique on the Physic-mechanical Characteristics, of Enalapril Maleate Tablets. The AAPS Annual Meeting, Toronto, Canada, Oct. (2002). 29. Fincher T. K., Mohsen I. Afouna, and Reddy I. K. Effect of the Physicochemical Characteristics upon the Permeability of Drug Using Chiral Terpene Enhancers. The AAPS Annual Meeting, Toronto, Canada, Oct. (2002). 30. T. K. Fincher, Mohsen. I. Afouna, I. K. Reddy. Effect of Thermodynamic Activity of Drugs and Chiral Terpene Permeation Enhancers upon the In-Vitro Flux of Selected Optically Active and Racemic Molecules across Hairless Mouse Skin. The AAPS Annual Meeting, Montreal, Canada, Oct. (2002). 31. Mohsen I. Afouna, Influence of Various Azone Concentrations upon Skin Target Site Free Drug Concentration (C*) of Bromovinyldeoxyuridine (BVDU) and Acyclovir (ACV) Formulations Using Hairless Mice: A Comparative Study. The AAPS Annual Meeting, Colorado, Denver, USA, Oct. (2001). 32. Mohsen I. Afouna, Ibrahim, E. A., Kassem, A and El-Shattawy, H Stability Characterization of Long-Acting Angiotensin Converting Enzyme Inhibitor; Enalapril Maleate Physical Mixtures with Selected Excipients Using Differential Scanning Calorimetry. The AAPS Annual Meeting, Colorado, Denver, USA, Oct. (2001). 33.EPS/AAPS/FIP workshop on the Bioequivalence Classification Systems, by the Egyptian Pharmacist Syndicate, Cairo, Egypt, Feb. (2000). 34.Mohsen I. Afouna, The in vivo Antiviral Efficacy of Cidofovir (HPMPC) and Acyclovir (ACV) Topical Formulations with or without Azone Against Cutaneous HSV-1 Infection in Hairless Mice Employing Different Treatment Protocols. 15th Annual Meeting of American Association of Pharmaceutical Scientists, Indianapolis, Indiana, USA, Oct. (2000).
6
35.Pharmex Consulting Group Workshop on Percutaneous Drug Absorption; Mechanisms-Methodology-Formulations Delivery-Toxicity, by Dr. Ghanem, A-H, and, Research Prof. of Pharmaceutics at the Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lack City, Utah, USA, March, (1999). 36.25th International Symposium on Controlled Release of Bioadhesive Materials, Controlled Release Society, Las Vegas, Nevada, USA. In. 21-24 Jun, 1998. 37. International Meeting of Biopolymers, Salt Lake City, UT,USA, March, 21. (1998) 38.Mohsen I. Afouna, Mehta, S. C., Ghanem, A-H., Higuchi, W. I., Kern, E. R., DeClercq, E., and El-Shattawy, H. Assessment of Correlation between the Skin Target Site Free Drug Concentration (C*) and the In-Vivo Efficacy for Bromovinyldeoxyuridine (BVDU) and Acyclovir Formulations in the Treatment of Cutaneous HSV-1 Infections in Hairless Mice, the 11th International Conference on Antiviral Research (Oral Session), San Diego, California, USA, (Oral Presentation), April (1998). 39.One-weak short course in “Safe Use of Radioactive Materials”, Dept. of Physics, the University of Utah, SLC, UT, USA. 40. Two-days workshop on “Ethics for Use Experimental Animal”, the University of Utah, SLC, UT, USA. 41. Mohsen I. Afouna, Mehta, S. C., Ghanem, A-H., Higuchi, W. I., Kern, E. R., DeClercq, E., and El-Shattawy, H. Absence of Correlation between C* Predictions and the In-Vivo Topical Antiviral Efficacy in Hairless Mice for Bromovinyldeoxyuridine (BVDU) Formulations. Twelfth Annual Meeting of American Association of Pharmaceutical Scientists, Boston, Massachusetts, USA, Nov. (1997). 42.Mehta, S. C., Mohsen I. Afouna, Ghanem, A-H., Higuchi, W. I., and Kern, E. R. The relationship of basal Cell Layer Drug Concentration (C*) to the Antiviral Efficacy: A Rigorous Evaluation of the C* Concept for Prediction of the Entire Range of Topical Efficacy of Acyclovir Formulations in the Treatment of Cutaneous HSV-1 Infections in Hairless Mice, The10th International Conference on Antiviral Research, Atlanta, Georgia, USA, April (1997). 43.Mehta, S. C., Mohsen I. Afouna, Ghanem, A-H., Higuchi, W. I., Kern, E. R., DeClercq, E., and El-Shattawy, H. Absence of Correlation between C* Predictions and the In-Vivo Topical Antiviral Efficacy in Hairless Mice for Bromovinyldeoxyuridine (BVDU) Formulations. The 11th Annual Meeting of American Association of Pharmaceutical Scientists, Seattle, Washington State, USA, October (1996).
O
RESEARCH INTEREST O SKIN RESEARCH: Design, preparation, development and characterizations of the various drug delivery systems particularly, TDDS/topical preparations intended for treatment of topical/systemic diseases. Study the effects the various physicochemical characteristics of the drug, skin penetration enhancers, and formulation-related variables. Design and developing of non-clinical methodologies for assessing skin target-site drug concentration from appropriate in vitro experiments using hairless mice as animal model and its correlation with the in vivo efficacy particularly antiviral agents. Mechanistic understanding of factors influencing predictivity of the in vitro-in vivo correlation. Investigating the formulation factors and dose regimens affecting topical efficacy of antiviral agents. O OPHTHALMIC RESEARCH: Study the effects the various physicochemical characteristics of the drug, penetration enhancers, and formulation*-related variables upon: The in vitro transcorneal permeability of the novel compounds across isolated rabbit corneal membrane. The in vivo IOP lowering effects for the formulation(s) containing anti-glaucoma agents using animal models. * Formulations such as ophthalmic gel, drops (solutions, suspension, emulsions) and liposomes. O
BIOPHARMACEUTICS/PHARMACOKINETICS RESEARCH: Design and determination of bioavailability, bioequivalence and pharmacokinetic parameters of systemic dosage forms employing compartmental and non-compartmental models.
7
O
SOLID DOSAGE FORMS: Characterization of drug-excepients interaction using Differential Scanning Calorimetry (DSC) technique. Study of the influence of tablet manufacturing technique on the physical characteristics, the in-vitro release, accelerated stability and shelf-storage stability of tablets.
o CO-INVESTIGATOR & APPLIED GRANT PROPOSALS 1. Grant-in-aid (SR 1.8 Million)/2-years for development of novel anti-diabetic drug delivery systems (PI), King Abdulaziz City for Sciences and Technology (KACST), King Abdulaziz University-Deanship or Scientific Research (KAU-DSR), (PI) 2. Grant-in-aid for Treatment of Prostatic Diseases Chair (Co-PI), KAU, (SR 3.00-Millions)/3-years. (CoPI) 3. Grant –in-aid for KAU-IRC, SR 110,800 for developing novel Dorzolamide Ophthalmic Solutions and Gels for Management Glaucoma in KSA. (PI) 4. A grant-in-aid to Thera-tech Inc., SLC, UT, USA, $± 70,000 for “Developing a Non-Clinical Methodology to Assess the Topical Efficacy of Various Antiviral Agents such as Acyclovir (ACV), Cidofovir (HPMPC ) and Bromovinyldeoxyuridine (BVDU). (Co-PI). O
TEACHING COURSES & ACADEMIC ACTIVITIES 1. Physical Pharmacy including, State of matter, Thermodynamics, Electrolytes and Non-electrolytes, Drug Stability and Reaction Kinetics, Solubility, Drug diffusion, International Phenomenon, Colloids, Coarse dispersions, suspensions & Gels. 2. Drug Delivery Systems and Pharmaceutical Dosage Forms including, ocular, topical & systemic liquid, semisolid, solid, sterile, and pressurized dosage forms. 3. Biopharmaceutics and Basic/Clinical Pharmacokinetics. 4. Pharmaceutical and Clinical Calculations.
o RESEARCH SKILLS & ATTRIBUTES PERCUTANEOUS & OCULAR DRUG TRANSPORT o Characterization of skin transport using side-bi-side/vertical Franz diffusion cells. o Characterization of corneal transport. o Design and conducting PK (bioavailability/bioequivalence) studies for systemic and local formulations. o Ex-vivo mucoadhesion and in vivo bioavailability assessment and correlation studies. o Impact of formulation-related factors on drug transport across biomembrane. ANALYTICAL o Experience with DSC, HPLC, UV and X-ray, Gamma Scintillation Counter. ANIMAL EXPERIMENTATION o Oral gavage of white albino mice. o HSV-type-I inoculation onto various laboratory animals. o Topical and parenteral treatment of hairless mice. o Ocular delivery using rabbits and SIRC cell line. o Isolation of rabbits’ cornea. o IOP evaluation using Tono Pens®. STATISTICAL Hands on experience with data analysis using statistical software such SPSS and others. O COMPUTER KNOWLEDGE
8
Operational ability in all major software on all windows such as: Microsoft office (Microsoft word, Excel, Power Point, one note, ..etc), COREL Office (Word perfect, Quatro-Pro, Corel Presentation), Adobe Illustrator, WinNonLin, graph bad, graph prism and many others. o COMMUNICATION/LEADERSHIP/TEAM WORK 1. Member of the Organizing Committee, Editorial Board Member, and Keynote Speaker , “The Pharma Middle East”, Dubai, UAE, November 02-04, (2015). 2. Chairman of the Organizing Committee, Editorial Board Member, OMICS International Global Pharmaceutical Summit,10-12 Aug., (2015). Philadelphia, USA. http://american.pharmaceuticalconferences.com/organizing-committee.php 3. Editorial Board Member, and Keynote Speaker, the International Conference on Pharmaceutical Sciences, Dubai on January 21-22, 2015. 4. Editorial Board Member, and Invited Speaker, 3rd ScienceOne Conference on Drug Discovery and Development Deira, Dubai, UAE, January 21-23, 2014, http://thescienceone.com/scddd 5. Chairman of “Egyptian Pharmacists for Pharmaceutical Research”, an NGO responsible for wide varieties of noble goals serving the entire Egyptian community (In the Establishing Procedures). 6. Chairman & member of Dept. of Pharmaceutics and Pharmaceutical Technology. 7. Member in College of Pharmacy Council, Al-Azhar University, Cairo, Egypt. 8. Member in the “Committee of Student Affairs”, COP, Al-Azhar University, Cairo, Egypt. 9. Primary author/co-author of several publications in peer-reviewed journals (see list above). 10. Active participant in several research projects requiring collaboration with other laboratories/researchers during M.S, Ph.D. and Post-doctoral work. 11. Director of “Union of Pharmacists for Pharmaceutical Research & Industries ” (UPPRI}, an NGO of about 15,000 pharmacists concerned with establishing a National Project for synthesis and mass production of pharmaceutical excipients and New Drug Molecule (NDM)s. We believe pharmaceutical industry is an essential part of “Egypt’s National Security”. 12. Chief and founder of the “Unit of Quality Assurance and Academic Accreditation (UQAAA) “College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 13. Chief and founder of the "Course Portfolio Committee”, College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 14. Member of the “IT Unite & Committee”, College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 15. Member of the “Libraries Committee”, College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 16. Member of the “Continuing Pharmacy Education Committee (CPE)”. College of Pharmacy, King Abdul Aziz University, Jeddah, KSA. 17. Member of the “The Department of Pharmaceutics Council” College of Pharmacy, KAU, Jeddah, KSA. 18. Saudi Arabia National Radio, “Around the Scientific Research Table” program, 2008. 19. Drafting a “Memo of Mutual Agreement” between King Abdulaziz University and the University of Arizona for Development of Pharm. D. Program, 2008-to-present. 20. Invited Speaker, Kuwait Health Sciences center, College of Pharmacy, 5/2005. 21. Teaching of different courses of pharmaceutical Sciences in the Department of Pharmaceutics, King Abdul Aziz University, Al-Azhar University, and Ain Shams University. 22. Member in the oral exam committee for many of the Colleges of Pharmacy in Egypt. o HONORS & ACHIEVEMENTS 1. Ranked first in overall academic rating at the College of Pharmacy at Al-Azhar University during many years of the undergraduate pharmacy study. 2. Two-year scholarship for Ph.D. study at the University of Utah, College of Pharmacy. 3. Up to 3-years post-doctorate & Research Scientist Fellowship from the School of Pharmacy at University of Arkansas for Medical Sciences (UAMS), LTR, AR, USA. 4. R & D Consultant for various Egyptian and Saudi Pharmaceutical Co. 5. Two Awards (Cash money and Honor Certificates) from KAU for outstanding research & publication (2011).
9
JOURNAL EXECUTIVE EDITOR, EDITORIAL BOARD, OR REVIEWER FOR TENS INTERNATIONAL JOURNALS INCLUDING: 1. International Journal of Pharmaceutical Sciences 2. Journal of Pharmaceutical Sciences 3. Journal of Bioavailability & Bioequivalence. 4. EC Pharmaceutical Science Journal by (E-Cornicon) 5. Open Journal of Ophthalmology 6. Letter of Drug Development Research. 7. Letter in Drug Design and Discovery. 8. Drug Development and Industrial Pharmacy. 9. Journal of Pharmaceutical Health and Research. 10. King Abdulaziz University Medical Journal. 11. European Journal of Pharmacy Biopharmaceutics. 12. Pharmaceutical Research. 13. Many others inter/national journals. ï‚· MEMBERSHIP 1. American Association of Pharmaceutical Scientist (AAPS). 2. International Pharmaceutical Federation (FIP). 3. Southern Region Discussion Group (SRDG). 4. Controlled Release Society, Inc. 5. American Association of College of Pharmacy (AACP) 6. American Association for Advancement of Science (AAAS). 7. Science Advisory Board (SAB). 8. Included in the Academic Keys Who's Who (2002, 2003 and 2008). 9. Included in the Academic Keys Who's Who in New York Health Sciences (2009). 10. The International Society of Antiviral Research. 11. Arab-American Association of Pharmaceutical Scientist (AAAPS). 12. Arab Life Sciences Network (ALSN). 13. Egyptian Pharmacist syndicate. 14. Saudi Council for Continuing Health Education (Official Trainer). REFERENCES: Available upon request.
10